Skip to main content
DrugPrice

Jardiance vs Ozempic

Side-by-side cost comparison based on Medicare Part D data

Jardiance costs 69% less per claim than Ozempic ($210.00 vs $685.00). A generic version of Jardiance is also available, which may reduce costs further.

Cost Per Claim

Jardiance$210.00
Ozempic$685.00

Medicare Spending

Jardiance$3.9B
Ozempic$5.0B

Beneficiaries

Jardiance2,150,000
Ozempic1,180,000

Annual Cost Per Patient

Jardiance$1,835.00
Ozempic$4,200.00

Full Comparison

MetricJardianceOzempic
Avg Cost Per Claim$210.00$685.00
Total Medicare Spending$3.9B$5.0B
Total Beneficiaries2,150,0001,180,000
Total Claims18,760,0007,240,000
Annual Cost/Patient$1,835.00$4,200.00
Year-over-Year Change+22.7%+72.5%
Generic AvailableYesNo
Patent ExpirationMay 23, 2025Sep 20, 2031
ManufacturerBoehringer IngelheimNovo Nordisk
ConditionDiabetesDiabetes
Generic NameEmpagliflozinSemaglutide

Jardiance vs Ozempic: What the Data Shows

Jardiance (Empagliflozin) and Ozempic (Semaglutide) are both used to treat diabetes. Based on Medicare Part D data, Jardiance costs $210.00 per claim, which is 69% less than Ozempic at $685.00 per claim.

Medicare spent $3.9B on Jardiance and $5.0B on Ozempic. In terms of patient reach, Jardiance serves more beneficiaries (2,150,000 vs 1,180,000).

Year-over-year spending changed +22.7% for Jardiance and +72.5% for Ozempic. Jardiance saw significant spending growth, suggesting increased utilization or price increases. Ozempic saw significant spending growth, suggesting increased utilization or price increases.

Jardiance has a generic available, while Ozempic remains brand-only until its patent expires Sep 20, 2031.

Frequently Asked Questions

Jardiance is cheaper at $210.00 per claim, compared to $685.00 for Ozempic. That makes Jardiance about 69% less expensive per claim based on Medicare Part D data.

Yes, both Jardiance and Ozempic are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.

Jardiance has a generic version (Empagliflozin) available, which is typically much cheaper. Ozempic is currently brand-only, with patent expiring Sep 20, 2031.

Medicare Part D spent $3.9B on Jardiance covering 2,150,000 beneficiaries, and $5.0B on Ozempic covering 1,180,000 beneficiaries.

Explore Further

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.